
UPDATES ON A LITIGATION PROCEEDING IN THE PEOPLE'S REPUBLIC OF CHINA

1. QUE Lippo Healthcare Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) wishes to update shareholders of the Company that a company known as Wuxi Hongshen Pharmacy Co., Ltd (“**Wuxi Hongshen**”) has commenced a creditor subrogation claim in the People’s Republic of China (“**PRC**”) against Wuxi Yilin Real Estate Development Co., Ltd (“**Wuxi Yilin Real Estate**”), a subsidiary of the Company, before the People’s Court of Xinwu District, Wuxi (the “**Subrogation Claim**”).
2. The Subrogation Claim was alleged on the following basis:
 - (a) Wuxi Hongshen was owed an outstanding sum of RMB 1.5 million by Wuxi New District Phoenix Hospital Co. Ltd (“**Wuxi Co**”) pursuant to a PRC judgement based on a contractual dispute case between the two parties (which does not involve the Group);
 - (b) Wuxi Yilin Real Estate did not pay the consideration for the land and building at No. 20 Changjiang North Road, New District, Wuxi Jiangsu Province acquired from Wuxi Co; and
 - (c) Wuxi Hongshen was therefore entitled to recover the outstanding sum of RMB 1.5 million (as a creditor of Wuxi Co.) directly from Wuxi Yilin Real Estate (as a subrogated debtor of Wuxi Co.) under PRC law.
3. On 16 September 2021, the Company was advised by its PRC counsel that there is no merit in Wuxi Hongshen’s claims, and will defend the proceedings vigorously.
4. On 17 September 2021, the Company’s PRC counsel attended an initial hearing before the People’s Court of Xinwu District, Wuxi, during which the Court gave directions on the submission of evidence by Wuxi Yilin Real Estate. As the amount claimed by Wuxi Hongshen is not significant, the Court instructed that it would apply a summary procedure for the matter (which involves a faster Court process) in accordance with the PRC Civil Procedure Law.
5. As and when there are material developments, the Company will provide further updates on the status of the above matter through SGXNet in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board
QUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
19 September 2021

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.